3D Global Biotech Inc.

As of June 30, 2026, 3D Global Biotech Inc. carries a market capitalization of 2.63B, placing it among publicly traded companies globally. Its enterprise value stands at 2.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, 3D Global Biotech Inc. has 76.98M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, 3D Global Biotech Inc. maintains a current ratio of 11.61, meaning it holds 11.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, 3D Global Biotech Inc.'s stock has declined approximately 31.65% over the past 52 weeks. The 50-day moving average sits at 33.29, while the 200-day moving average is 35.60.

As of June 30, 2026, 3D Global Biotech Inc. holds 497.11M in cash and equivalents against 45.16M in total debt, resulting in a net debt position of -30.34M. Total book value stands at 732.73M, with working capital of 503.57M providing operational flexibility.

3D Global Biotech Inc.'s most recent stock split took place on July 31, 2024 with a 218:221 split ratio.